Abbott Laboratories (ABT.N)
76.34USD
3:44pm BST
$0.24 (+0.32%)
$76.10
$75.96
$76.38
$75.67
214,342
1,848,746
$80.67
$56.81
About
Overall
| Beta: | 1.09 |
| Market Cap(Mil.): | $133,667.41 |
| Shares Outstanding(Mil.): | 1,756.47 |
| Dividend: | 0.32 |
| Yield (%): | 1.68 |
Financials
| ABT.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 51.22 | 34.07 | 63.23 |
| EPS (TTM): | 1.49 | -- | -- |
| ROI: | -- | 12.63 | 11.76 |
| ROE: | -- | 14.88 | 12.60 |
Abbott Labs quarterly beat overshadowed by unchanged forecast
Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.
UPDATE 2-Abbott Labs quarterly beat overshadowed by unchanged forecast
April 17 Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.
Abbott Lab's first-quarter sales beat expectations
April 17 Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.
Abbott misses revenue estimates, sees lackluster first-quarter profit
Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.
UPDATE 3-Abbott misses revenue estimates, sees lackluster first-qtr profit
Jan 23 Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.
Abbott Labs says M&A not a high priority now
Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.
Abbott Labs says M&A not a high priority now
Jan 23 Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.
Abbott Lab's fourth-quarter revenue rises 2.3 pct
Jan 23 Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.
Abbott, AbbVie settle TriCor marketing case for $25 million
Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.
UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln
Oct 26 Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.
Estimates